Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 2/20 | 0.57 |
| ▸ | PIM1 | P11309 | 1/20 | 0.55 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.55 |
| ▸ | MAOA | P21397 | 1/20 | 0.45 |
| ▸ | MAOB | P27338 | 2/20 | 0.42 |
| ▸ | PGR | P06401 | 1/20 | 0.40 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.37 |
| ▸ | CA12 | O43570 | 1/20 | 0.34 |
| ▸ | CA9 | Q16790 | 1/20 | 0.34 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.34 |
| ▸ | MMP1 | P03956 | 1/20 | 0.34 |
| ▸ | MMP2 | P08253 | 1/20 | 0.34 |
| ▸ | MMP3 | P08254 | 1/20 | 0.34 |
| ▸ | MMP7 | P09237 | 1/20 | 0.34 |
| ▸ | MMP9 | P14780 | 1/20 | 0.34 |
| ▸ | MMP12 | P39900 | 1/20 | 0.34 |
| ▸ | MMP13 | P45452 | 1/20 | 0.34 |
| ▸ | MMP14 | P50281 | 1/20 | 0.34 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18001848 | 0.87 | CYP2A6 (0.51) | CYP2A6PIM1PIM2MAOAMAOB | |
| SCHEMBL18002662 | 0.81 | NFE2L2 (0.50) | CYP2A6PIM1PIM2MAOAMAOB | |
| SCHEMBL18002927 | 0.80 | CYP2A6 (0.44) | CYP2A6PIM1PIM2PGRFFAR1 | |
| SCHEMBL18003174 | 0.78 | PGR (0.46) | CYP2A6PIM1PIM2MAOBPGR | |
| SCHEMBL18002708 | 0.78 | CYP2A6 (0.47) | CYP2A6MAOBPGRCA12CA9 | |
| SCHEMBL118925 | 0.77 | CYP2A6 (0.62) | CYP2A6PGRCA12CA9 | |
| SCHEMBL2056266 | 0.76 | PIM1 (0.46) | PIM1PIM2MAOAMAOBFFAR1 | |
| SCHEMBL5144216 | 0.74 | CYP2A6 (0.65) | CYP2A6 | |
| SCHEMBL18002504 | 0.74 | PGR (0.59) | CYP2A6MAOBPGRCA12CA9 | |
| SCHEMBL2056271 | 0.73 | PIM1 (0.43) | PIM1PIM2MAOAMAOBFFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11420944-B2 | Voltage-dependent t-type calcium channel blocker | NIPPON CHEMIPHAR CO., LTD. (JP) | 2022-08-23 | — | — | US | disclosed |
| US-20190077767-A1 | VOLTAGE-DEPENDENT T-TYPE CALCIUM CHANNEL BLOCKER | NIPPON CHEMIPHAR CO., LTD. (JP) | 2019-03-14 | — | — | US | disclosed |
| EP-3404021-A1 | VOLTAGE-DEPENDENT T-TYPE CALCIUM CHANNEL INHIBITOR | Nippon Chemiphar Co., Ltd. (JP) | 2018-11-21 | — | — | EP | disclosed |
| WO-2004069829-A1 | (2S)-2-((PYRIMIDIN-4-YL)AMINO)-4-METHYLPENTANOIC ACID AMINOETHYLAMID DERIVATIVES AS IL-8 RECEPTOR MODULATORS FOR THE TREATMENT OF ATHEROSCLEROSIS AND RHEUMATOID ARTHRITIS | PHARMACOPEIA DRUG DISCOVERY, INC. (US) | 2004-08-19 | — | — | WO | disclosed |
| WO-2004063192-A1 | IMIDAZOLYL PYRIMIDINE DERIVATIVES USEFUL AS IL-8 RECEPTOR MODULATORS | PHARMACOPEIA DRUG DISCOVERY, INC. (US) | 2004-07-29 | — | — | WO | disclosed |
| US-20030055084-A1 | Pharmaceutical compounds and methods of use thereof | MILLENNIUM PHARMACEUTICAL, INC. | 2003-03-20 | — | — | US | disclosed |
| WO-2003011848-A1 | BENZOHETEROCYCLES AS LIPOXYGENASE INHITIBORS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2003-02-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030055084-A1 | Pharmaceutical compounds and methods of use thereof | CYP3A5, DHPS, CYP3A43 | CYP2A6 41/4885PIM1 944/4885PIM2 1096/4885 |
| US-11420944-B2 | Voltage-dependent t-type calcium channel blocker | CACNA1I, CACNA1G, CACNA1E | CYP2A6 1405/4885PIM1 4613/4885PIM2 3726/4885 |
| US-20190077767-A1 | VOLTAGE-DEPENDENT T-TYPE CALCIUM CHANNEL BLOCKER | CACNA1I, CACNA1G, CACNA1E | CYP2A6 1475/4885PIM1 4679/4885PIM2 4031/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.